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The curation of genetic variants from biomedical articles is required for various clinical and research purposes. Nowadays, establishment
of variant databases that include overall information about variants is becoming quite popular. These databases have immense utility,
serving as a user-friendly information storehouse of variants for information seekers. While manual curation is the gold standard method
for curation of variants, it can turn out to be time-consuming on a large scale thus necessitating the need for automation. Curation of
variants described in biomedical literature may not be straightforward mainly due to various nomenclature and expression issues.
Though current trends in paper writing on variants is inclined to the standard nomenclature such that variants can easily be retrieved,
we have a massive store of variants in the literature that are present as non-standard names and the online search engines that are pre-
dominantly used may not be capable of ﬁnding them. For eﬀective curation of variants, knowledge about the overall process of curation,
nature and types of diﬃculties in curation, and ways to tackle the diﬃculties during the task are crucial. Only by eﬀective curation, can
variants be correctly interpreted. This paper presents the process and diﬃculties of curation of genetic variants with possible solutions
and suggestions from our work experience in the ﬁeld including literature support. The paper also highlights aspects of interpretation of
genetic variants and the importance of writing papers on variants following standard and retrievable methods.
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Information about genetic variants in biomedical literature
is already extensive and will increase exponentially in
future as we are embarking on whole genome sequencing
using high throughput next generation sequencing (NGS)
technology [1]. While it is time-consuming to manually
curate genetic variants from such an extensive and ever
growing literature, automated tools that speed up curation
are evolving or already in use [2,3]. Although automated
curation is fast, nomenclature and presentation issues of1672-0229/$ - see front matter  2012 Beijing Institute of Genomics, Chinese A
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E-mail: maden.narendra@gmail.com (Maden N).variants as well as false positive and negative results inher-
ent to the process lower the sensitivity and speciﬁcity [4].
Manual curation is adopted as the gold standard and used
to compare the qualitative measures of automated tools.
Most databases of variants rely on manual curation for
data extraction and entry [5]. There are nearly 2000
locus-speciﬁc databases (LSDBs) or variant databases
which serve as web-based platforms for submission, repos-
itory and extraction of overall information of variants [6,7].
While a LSDB can be built using speciﬁc guidelines, stan-
dard guidelines for establishing all LSDBs have been
described by Vihinen et al. [7], which include the essential
steps for the establishment, maintenance, information
structure and ethics of LSDB. Furthermore, steps on thecademy of Sciences and Genetics Society of China. Published by Elsevier
318 Genomics Proteomics Bioinformatics 10 (2012) 317–325development of a centralized database have been made to
better manage the deluge of variant data coming from
whole genome sequencing via NGS [1,8]. For broad utility
in clinical practice and research, variant databases should
contain information regarding genotypic and phenotypic
information, consequences of variants (predictive, struc-
tural and functional), and clinical and demographic data.
Moreover, it is of utmost necessity to gather maximum
information about variants before drawing any conclusions
about their disease-causing potentials. Thus, it is necessary
to understand thoroughly what diﬃculties surround the
curation and ways to solve them eﬀectively. In this paper,
we discuss the steps and diﬃculties in curation with their
possible solutions, automated curation, aspects of interpre-
tation of the variants and importance of following a stan-
dard nomenclature of variants.
Curation of variants
Curation of variants should start with ascertaining refer-
ence sequences, standard ontology and nomenclature sys-
tem of genes and proteins [7,9,10]. Gene selection for
curation can be adopted as phenotype- or gene-speciﬁc; a
common practice is to select a genetic disease and then con-
sider all its linked genes for curation. Which and how many
genes are required for curation is dependent upon the ﬁnd-
ings from linkage analysis, genotype-phenotype correlation
and genome wide association study (GWAS). Information
from genetic testing and counseling bodies, online Mende-
lian inheritance in man (OMIM), and phenotype-speciﬁc
online databases (such as catalogue of somatic mutations
in cancer (COSMIC)) are also useful for identifying genetic
links to disease. Reference DNA and protein can be pro-
cured from NCBI (http://www.ncbi.nlm.nih.gov/gene-
bank/index) and UniProt (www.uniprot.org), respectively.
Recently, locus reference genome (LRG) reference sequence
is gaining popularity to obtain reference sequences of DNA
and protein (www.lrg-sequence.org/) [11]. Likewise, many
databases may also provide reference DNA and protein
sequences.
Use of diﬀerent internet search engines (such as Pub-
Med, Scholar Google and Google) and databases has
become routine practice in obtaining relevant literature
[12]. PubMed is one of the richest sources of biomedical
papers citing over 21 millions papers. A list of common
public databases for genetic variants can be found at
human genome variation society (HGVS) (http://
www.hgvs.org/dblist/glsdb.html) and UMD database
(http://www.umd.be/). By using Boolean queries (single
or combined form) and similarity-query, papers are mostly
extracted manually but an automated method has also
been used to extract a large set of literature [4,13,14].
Essentially, search strings to extract papers on variants
should include the following terms: gene name(s) / protein
name(s) / phenotype(s) / genetic or gene variant / variant /
types of genetic variants / variation / polymorphism /
[15,16]. For example, search strings utilized to extractpapers for Cystic ﬁbrosis transmembrane regulator
(CFTR) gene variants should include: (CFTR) (mutations)
/ (CFTR) (genetic variants or gene variants) / (CFTR)
(Cystic ﬁbrosis or CF) / CFTR) (pancreatitis) (mutations
or variants) / (CFTR) (congenital absence of vas deferens
or CAVD) (mutations or gene variants or variants) /
(CFTR) (variation or polymorphism) / (CFTR) (missense
mutation) / (cystic ﬁbrosis) (frequency) (mutations) /
(CFTR) (gene functions). For a variant-speciﬁc search, a
number of search strings can be applied utilizing gene name
and descriptive phrases of the variant. The search strings
vary according to the type of variants and correction fac-
tors. Legacy names of variants, if present, must always
be included. The limitation of an internet search is that
the variants listed only in tabular forms, image ﬁles, and
supplementary materials may not be retrieved eﬀectively.
A stepwise ﬂowchart for the curation of variants taking
an example for the CFTR gene is presented in Figure S1.
Diﬃculties in curation and their possible solutions
Curation of variants requires meticulous work and the
curator has to tackle many diﬃculties such as nomencla-
ture issues, typos, and errors in papers [17]. Many prob-
lems can be gene-speciﬁc: for example, in the past, legacy
names for HBB gene variants used to be assigned by geo-
graphical names such as Hb N-Baltimore, Hb D-LA, Hb
O-Panjab, etc. In contrast, legacy names of CFTR variants
followed the standard numbering of amino acids. Regular
expression of variants and correction factors also diﬀer
among genes. During curation, nomenclature issues are fre-
quent imposing major diﬃculties [17]. At times, variants
are not decipherable by the standard nomenclature.
Nomenclature issues should be prioritized at topmost for
disambiguation because, if a variant that accompanies
important information is not retrievable due to such an
issue, interpretation of the variant in a clinical setting
might be misleading.
Nomenclature issues
Variants are presented in a paper following a speciﬁc
nomenclature. However, disparate conventions as well as
nonstandard naming of variants across the literature may
be encountered. To maintain uniformity, standard nomen-
clature recommended by HGVS (http://www.hgvs.org/
mutnomen) should be followed [17]. Some of the important
aspects of this nomenclature system are reiterated below.
(i) Numbering of variants at the cDNA level should start
from the translation initiation site. Naming of substitution
variants should be in the form ‘c.# wild-type nucleo-
tide>mutated nucleotide’(such as c.372G>A). For deletion
and insertion variants, formats are ‘c.#del (or ins) nucleo-
tide’(such as c.42delC; c.1_2insC) for single nucleotide
involvement, and ‘c.#_#del (or ins) nucleotides’ for multi-
ple nucleotide involvement (such as c.1_2delAT and
c.1_2insCCTAC). Large deletion and insertion variants
Pandey KR et al / Solving the Diﬃculties in Curation 319format is: ‘c.#_#del (or ins) number of nucleotides’ (such
as c.20_60del42; c.20_21ins21). Though it is not obligatory,
for deletion and insertion variants that involve fewer than
20 nucleotides, all deleted or inserted nucleotides should be
mentioned. Wherever applicable, deletion and insertion
variants especially in coding regions should be expressed
at the most 3’ position and insertion variants should be
duplicated. However, an insertion variant in intronic or
untranslated regions should not be 3-primed so as to
extend to the coding region. For example, DSP variant
c.-1_1insA should not be expressed as c.1dupA. For indel
variants, format should be ‘c.#delins nucleotide(s)’ and
‘c.#_#delins nucleotides’ (e.g., c.4delinsT; c.4_6delinsA;
c.4_5delins40; c.del4_5CCinsA etc). An intronic substitu-
tion should be reported as the relative distance from
exon-intron or intron-exon boundary (such as IVS10+
1G>A; c.490+1G>A that lies downstream of the exon
and IVS10-G>A; c.550-1G>A that lies upstream of the
exon). For intronic deletions, insertion and indel variants,
the same rules apply as in coding region; only the formats
are diﬀerent (examples: IVS10+25delA; c.490+25_490+
26dupA; c.490+25_490+35delinsAAT; etc). For untrans-
lated regions (UTR), the formats can be represented as
c.-12A>G and *57C>G or c.*+57C>G for the 5’UTR
and 3’ UTR, respectively.
(ii) Amino acid numbering should start from the trans-
lation initiation codon counted as ﬁrst amino acid. Use
of three-letter codes for amino acids should be emphasized;
however, one letter codes are also extensively used for pre-
sentational ease. For missense mutations, the format is
‘p.wild-type amino acid# mutated amino acid’ (such as
p.Thr124Ile or p.T124I). Similarly, synonymous variants
should be represented as p.Thr124Thr. Substitution at
the initiation codon should be expressed as ‘p.Met?’ and
at stop codon as ‘p.#mutated amino acid ext*#’
(p.117Trpext*25). For nonsense mutations, the format
can be represented as Gln243X, p.Gln243* or p.Gln243Ter
and for frameshift mutations, it is p.Gln243fsX35. For cod-
ing in-frame deletion variants, the formats are ‘p.wild-type
amino acid#del’ and ‘p.wild-type amino acid# _wild-type
amino acid #del’ (p.Gln243del, p.Gln243_Leu244del). In the
same ways, formats can be represented as p.Gln243insGly,
p.243Gln_244LeuinsGly, p.Gln243dup, p.Gln243_Leu244dup
for insertion and duplication variants and as p.243delins-
Leu and p.243Gln_244LeudelinsProGly for indel variants.
For recessive diseases, two variants in the same allele
should be expressed as p.[(variant;variant)] and in
diﬀerent alleles or in the compound heterozygous state as
p.[(variant)];[(variant)]. When only one variant is identiﬁed
the format is p.[variant];[?] and when one allele carries a
variant while the other is normal, the format is
p.[variant];[=].
(iii) Genomic numbering starts from the ﬁrst nucleotide
of the gene and should be represented by the suﬃx ‘g.’. The
format for genomic numbering involving substitution is
‘g.# wild-type nucleotide>mutated nucleotide’ (for exam-
ple g.345555A>G).Although the majority of papers use the translation ini-
tiation site as the start of numbering, depending upon
genes, it is common to ﬁnd papers that start numbering
from other sites such as the transcription initiation site,
speciﬁc domain of a protein, and signal or leader peptide
in some proteins. Numbering system includes both plus
and minus numerals excluding zero. Positional discordance
of nucleotide or amino acid numbering between paper and
reference sequence has to be resolved by calculating correc-
tion factor. For example, in the nomenclature of CFTR
gene variants, although amino acid numbering starts from
the translation start in both older and standard nomencla-
ture systems, nucleotide numbering in the older nomencla-
ture starts from the transcription initiation site which is 132
nucleotides upstream of the translation start [17]. Similarly,
in LDLR gene, many older papers used numbering starting
from the signal peptide which is 21 amino acids upstream
of the initiation codon following the LDLR sequence
described by Yamamoto et al. [18]. Mostly, the correction
factor calculated for a gene applies to all its variants
described in the literature.
Nucleotide numbering issues. In many papers, the amino
acid numbering of variants is usually the same for papers
as well as reference sequence but numbering of the nucleo-
tide sequence may vary. Suppose in a paper, a variant in a
gene is provided as: 608G>A (G202D). If the nucleotide at
position 608 in that gene is ‘C’ in the reference sequence,
numbering of the nucleotide is diﬀerent between the paper
and reference sequence. In the latter, if the amino acid at
codon 202 is Gly, it means that numbering of the amino
acid sequence is identical in both. If Gly 202 is encoded
by GGC (c.604-606) in the reference sequence, the nucleo-
tide change given in the paper therefore is c.605G>A in ref-
erence numbering. Thus the correction factor is paper -3
nucleotides= reference nucleotide. In the CFTR gene,
nucleotide numbering in older nomenclature starts from
the transcription start site which is 132 nucleotides
upstream of the ‘A’ of initiation codon. Hence, +1 nucleo-
tide in standard numbering represents +133 in older
numbering. Thus +133, +134, +135, +136, +137,. . . in
older numbering converts to +1, +2, +3, +4, +5,. . .,
respectively, in standard numbering which gives correction
factor: paper -132 nucleotides= reference nucleotide.
Similarly, +132, +131, +130, +129,. . . in older numbering
converts to 1, 2, 3, 4,. . ., respectively, in standard
numbering which gives the correction factor: paper -133
nucleotides=reference nucleotide [19]. In some papers only
legacy names of variants are given resulting in ambiguity at
ﬁrst sight, for example, T/TG counts at intron 9 of CFTR
and legacy names for HBB variants. Standard names for
such variants can be determined by observing their descrip-
tions in multiple papers published over a range of years and
by using information from public databases.
Amino acid numbering issues. To describe variants at the
amino acid level, authors may not always use standard
numbering for some genes. Suppose for a gene, variants
are mentioned in a paper as G204A, R216W, K236X,
320 Genomics Proteomics Bioinformatics 10 (2012) 317–325and M250V. In the reference protein sequence, if these
amino acids are found at codons 201, 213, 233 and 247,
respectively, the correction factor is paper-3 amino acids
= reference amino acid. Use of the correction factor in
papers may be diﬀerent depending on the positions because
there is no zero in numbering schemes (i.e., 1 is followed by
1). For example, suppose numbering schemes of amino
acids of a protein in nomenclature systems A and B are
3, 2, 1, 1, 2, 3,. . . and 1, 1, 2, 3, 4, 5,. . ., respectively,
such that amino acid ‘3’ in nomenclature system A repre-
sents amino acid ‘5’ in nomenclature system B and so on.
In this situation, the correction factor to get from A to B
is A + 3 = B if A is negative and B is positive (e.g., at
A = 2); but it is A + 2 = B if both A and B are either neg-
ative (e.g., at A = 3) or positive (e.g., at A = 1). For
example, in growth hormone 1 (GH1) gene, numbering
of the amino acid in the new nomenclature system starts
from initiation codon of leader peptide which is 26 amino
acids upstream of the numbering start in old nomenclature.
In old numbering system, a leader sequence used to be indi-
cated by minus numbering. Hence +1 in old numbering is
+27 (1 + 26) in reference numbering and 1, 2, 3, 4,
5, 6,. . . in older numbering system converts to +26,
+25, +24, +23, +22, +21,. . ., respectively, in reference
numbering system, giving the correction factor paper+27
amino acids = reference amino acid. Similarly, +1, +2,
+3, +4, +5. . . in older numbering converts to +27, +28,
+29, +30, +31,. . ., respectively, in reference numbering
system, giving the correction factor paper+26 amino
acid = reference amino acid [20].
Degenerate codon. Papers that mention variants only at
the amino acid level may result in ambiguity due to the
presence of degenerate codons when deriving such variants
at the cDNA level. For example, if Leu (suppose encoded
by TTA) is mutated to Phe, the change will either be
A > C or A > T. Here, either both nucleotide changes have
to be considered or the corresponding author of the paper
has to be contacted to ascertain the cDNA change. Public
databases can also be checked to clarify such ambiguous
variants. Since it is DNA which is sequenced and not pro-
tein, authors should understand that giving only amino
acid changes is providing the consequences only, not the
actual changes. If possible, it is good practice to mention
nucleotide as well as amino acid changes of the coding vari-
ants. Some synonymous variants can form cryptic splice-
sites for which giving nucleotide changes is more relevant.
For example, hemoglobin beta (HBB) gene variant
c.75T>A leads a silent change (p.Gly25Gly) but the variant
is demonstrated to result in skipping of exon 2 by activat-
ing a cryptic splice-site and hence is disease-causing [21].
Inter-conversion of nucleotide numbering. Exonic as well
as intronic variants should preferably be mentioned at
the cDNA level to reﬂect their eﬀects on translation.
Knowing relative positions of intronic variants from
exon–intron boundaries is informative because variants at
splice-sites are deleterious. For example, it is better to
express a CFTR variant as c.489+1G>T than its genomicnumbering (AJ574942.1) g.240G>T [13]. To get cDNA
numbering of a genomic variant, manual as well as auto-
mated sequence alignment can be done. For manual con-
version, alignment of genomic variant over full length
cDNA sequence should be performed using a repetitive
sequence a few nucleotides upstream or downstream of
the variant. Genomic numbering can also be changed to
cDNA numbering by software tools that perform the task
by a sequence alignment process. By utilizing Mutalyser
(https://www.mutalyzer.nl/), numbering of a genomic var-
iant can easily be converted to its cDNA numbering.Referencing issues of single nucleotide polymorphisms
Single nucleotide polymorphisms (SNPs) may be presented
in NCBI dbSNP as referenced complementarily to that of
reference sequence. To get the correct nucleotide change
and the frequency data of alleles, alignment of sequence
ﬂanking the SNP with the reference sequence is required.
For example, FASTA sequence of rs35062203 (ALMS1
gene) in dbSNP is given as GGGGAGAATG[S]TTTT
CTCTCA (8822-8842) where ‘S’ represents C or G at
c.8832. The reverse complementary sequence is TGAGA
GAAAA[S]CATTCTCCCC. The reference sequence for
ALMS1 NM_015120 in this region is TGAGAGAAA
A(C)CATTCTCCCC where C is present at 8832. Since
negative strand has been referenced in this case, variant
allele (i.e., minor allele) in FASTA sequence is C at 8832.
Hence, while using the variant allele’s frequency informa-
tion from population diversity data forc.8832C>G, data
of C must be used, not of G. Thus, dbSNP data are
strand-dependent which is indicated on ‘Primary Assembly
Mapping’ row at SNP to Chr column. The UCSC genome
browser provides reference sequences as well as dbSNP
dataset aligned to the positive strand (http://www.geno-
me.ucsc.edu/cgi-bin/hgTables?command=start), which
can be used directly without need for sequence alignment.Others
A gene can have more than one alias but papers may not be
consistent in using a particular name for it. To standardize
the use of gene symbols, the human genome organization
gene nomenclature committee (HGNC) approved that gene
symbols (http://www.genenames.org/) should be used by
all authors, curators and databases. Furthermore, for some
genes, the curator has to discriminate pseudogene-speciﬁc
variants that have no pathological roles by examining the
experimental set-up in the paper. Similarly, a protein can
have more than one isoform; hence, the standard mRNA
isoform of the protein should be predetermined. Papers
usually provide information about reference proteins
(either mRNA accession or UniProt or Ensemble ID); if
such information is not given, a few other papers related
to that protein need to be examined to determine the stan-
dard isoform of the protein. Primarily, the longest and
Pandey KR et al / Solving the Diﬃculties in Curation 321most predominantly expressed isoform of a protein should
be utilized for curation.
Because primary research papers provide original
reports of variant-related information, they should be pri-
oritized for the curation. It is often found that, if an origi-
nal paper has mentioned variants only at the amino acid
level, writers citing the variants from that paper do not
mention the variants at the cDNA level. Similarly, if vari-
ants in a primary paper are ambiguous due to nomencla-
ture or other issues, authors of secondary papers may not
resolve the ambiguities. It should be the responsibility of
authors who cite the primary papers to clarify any ambig-
uous variants. Even if colloquial and/or legacy names of
variants need to be retained, the authors should provide
their standard names as well.
In papers reporting a large number of variants, posi-
tional and alphabetical typos for the amino acid and nucle-
otide changes may be encountered. For papers that provide
both amino acid and DNA changes of the variants, the
numbering that is consistent with that of the reference
sequence should be used to derive their standard names.
In rare cases, lack of uniformity in using single letter code
for amino acids might be encountered in old papers. For
example, papers may use ‘L’ to denote leucine or lysine,
‘B’ for aspartic acid or asparagine, ‘P’ for proline or phen-
ylalanine and ‘Z’ for glutamate or glutamine. Many papers
are also written in native languages that contain genetic
variants which need to be translated to the language cura-
tors require.Table 1 Common automated mutation curation tools and their extraction strat
Tool Extraction approach Extraction pair
MuteXt Regular expression,
word proximity,
Swiss-Prot entry
Variant-protein
(at amino acid level)
MEMA Regular expression,
word proximity
Variant – gene
(at amino acid and DNA
Mutation GraB Regular expression,
graph metric, sequence check
Variant–protein–organism
(at amino acid level)
Mutation miner Regular expression,
sentence co-mention
Variant-organism
(at amino acid level)
Mutation ﬁnder Regular expression Gene-variant
(at amino acid level)
Yip et al., 2007 Regular expression,
rule-based system
Gene-variant
(at amino acid level)
coagMDB Regular expression,
graph metric, sequence check
Gene-variant
(at amino acid level)
MuGeX Regular expression Gene-variant
(at protein and DNA lev
Krallinger et al.,
2009
Regular expression,
residue disambiguation
and classiﬁcation
Gene-variant (at protein
natural vs artiﬁcial varian
PolySearch Sentence co-mention,
word association
SNP detection; gene-vari
Note: U indicates undetermined; #, G-protein-coupled receptor (GPCR) muta
were tested by MEMA for cited mutations in one letter code for variant-gene
respectively. P, precision; R, recall; F, F-score. See more details in the text.Automated curation
To curate variants, automated curation tools use expression
patterns such as annotation of variants, contextual features,
distance-metrics, graph-metrics, and rule-based systems
such as pattern matching. For example, two common tools
MEMA and MuteXt have been developed that can use a
dictionary search for protein and gene names and diﬀeren-
tiate protein names based on the measurement of word
proximity distance for extraction of variants: a variant in
a paper is closer to the names of its related genes/proteins
rather than names of other proteins/genes that are also
present in the paper [16,22]. There are many automated
tools that mainly diﬀer on extraction strategies and eﬃ-
ciency. A list of common automated tools and their extrac-
tion strategies are brieﬂy presented in Table 1. Though
variants curated using automated tools need to be validated
for false positive (FP) and false negative (FN) results, less
time and resources needed make them attractive for the
construction of large LSDBs. Many of them just curate
the variants mainly from Medline abstracts but a few have
been reported that can curate the variants from full text
papers [16]. Moreover, automated tools that can check
the nomenclature of the variants have also been developed.
Mutalyzer (http://www.lovd.nl/mutalyzer/), a web-based
software application, can be used for assessment of nomen-
clature of the variants extracted from publications [2]. Sim-
ilarly, a web-based software application called COMUS can
detect not only variants from sequencing ﬁles (AB1 ﬁlesegies and quality measures
Literature set used Quality measures
(P; R; F)
Refs
GPCR and NR protein
related full texts and abstracts
0.87; 0.87; U# [26]
levels)
Medline abstracts 0.93;0.35;U* [4,16]
Full text articles 0.84;0.90;0.87 [16]
Abstracts 0.91;0.46;0.61 [10,16]
Full text articles 0.98;0.81;0.81 [31]
Full text articles 0.89;U;U [32]
Full text articles;
serine protease
87-93;96-99;U [33]
els)
Medline abstracts;
Alzheimer’s disease
associated genes
88.9;91.3;U [34]
level);
ts
Abstract and full text
articles; kinase protein
72;U;U and
93.88;U;U for
natural vs artiﬁcial
variants
[35]
ant Abstracts, full text articles U;U;U [36]
tions; NR, nuclear hormone receptor. * For example, when 100 abstracts
extraction pair, the quality measures, P and R values, were 0.93 and 0.35,
Table 2 Descriptive patterns or expression of variants in literature
Level Descriptive phrases
Amino
acid
Missense p.Arg30Gln; Arg30Gln; R30Q; Arg30 to Gln; Arg30 > Gln; Arg30! Gln; Arg30Gln; Arg30toGln; Arg(30)-Gln;
Arg-30! Gln; Arg30!Gln; Gln30; 30Gln; Arg/Gln at codon 30; Arginine to Glutamine (substitution) at (codon)
30; Arg > Gln change at amino acid 30; Glutamine for Arginine at residue 30; RQ30; Q30; Arg30!Gln
Nonsense R30X; p.Arg30X; R30Ter; R30*. R30Stop
Frameshift R14fsX4; DeltaR30; DR30; 30delArg; Ins30Arg; deletion (or insertion) at codon 30
Silent R30R; Arg30Arg; p.Arg30=; p.Arg30Arg.
DNA Substitution c.90G>A; G90A; 90G/A; G-90>A; 90!A; 90G-A; G(90)!A; UTR: c.-90G>A; -90 G!A; G to A at -90;
c.*90G>A; c.*+90G>A
Frameshift c.90delG; c.90del; 90delG; c.90insG; 90insG; 90del2; 1-bp del, 90G; c.89_90insG; c.89_90delinsA; 90delinsA;
c.90dupG; insertion of G at position 90; Arg30fsX2; R30fs; insertion (or duplication) of G at position 90; deletion of
2 bp at codon 30.
Intronic A to G at splice acceptor of intron 2; IVS31AS, A-T, -2; 3061(-1)G –> A; IVS32DS, G-A, +1; IVS2-2A>G;
IVS2+1G>A; IVS2+1(G>A); Intron 2 nt-51A>G; 401(-1)G –> A; IVS1, G-A, -1; c.400+30A/G; c.400+30A>G;
400+30A>G; c.-8C>G; Intron 2 (-8G->A); IVS1+15del3; 400+30delG; 400+30insG; etc.
Large deletions/
duplications
### bp deletion; del exon 1, c.del exons 2_4; c.dup exons 2_4; etc.
SNP rs# or ss#; for example: rs5495
Haplotype Haplotype description is gene/locus speciﬁc; for example, (TG)m(T)n, i.e., TG and T repeats at intron 9 of CFTR
gene: 7T, 5T, 5T/TG10, etc.
322 Genomics Proteomics Bioinformatics 10 (2012) 317–325from Sanger sequencing) but also check the HGVS compli-
ant nomenclature of variants [23].
Parameters for automated curation
Variants can be described mainly at ﬁve levels: (i) DNA
level, (ii) amino acid level, (iii) SNP (in the form of rs or
ss number), (iv) haplotype and (v) RNA level. Though vari-
ants are predominantly described at DNA and amino acid
levels, authors also present some variants as haplotype, rs
record and RNA change. Authors provide the DNA and/
or amino acid change of variants mentioned at RNA level.
Apart from a speciﬁc nomenclature, variants are also men-
tioned in papers using annotations or phrases which form
various expression patterns. The various descriptive ways
by which variants are presented in biomedical literature
are given in Table 2. For automated curation tools, these
form signaling texts which have to be read and extracted
precisely [17,24,25]. Various automated tools use diﬀerent
strategies to extract variants but organism-gene-variant
extraction pair is the most speciﬁc. To exclude FP results,Table 3 Mutation-like terms and overlapping names that need to be validated
Item Description
Cell lines T47D (breast cancer cells); L5178Y (lymphoblasts); C33
H293K, T98G (Human glioblastoma cell lines); M14T (T
T20C (cancer cell lines); etc.
Gene names L23A, E2F, H4M, ER, etc.
Protein names A2V, S100D, S100C, S100E, P34S(sperm surface protei
Taxonomic
entities
Escherichia coliK12S; A. Viscous T14V, Pneumocystis pn
spp. F713E, Bacillus spp. G100I, Candida spp. N12C, Sy
identiﬁers (eg W12I and W12E), plasmids (eg E. coli pla
Overlapping
names
A13G, C13T.
Others M24R (ﬁlter); A83586C (antibiotic), A27L (immunogenpoint mutation-like terms and overlapping expressions
(Table 3) should be created along with their contextual
meanings and used for the validation of variants curated
by automated tools [13,26].
Three parameters—precision, recall and F-score can be
used to assess the quality of curation by automated tools
[16]. Manual curation results serve as the gold standard
or reference for evaluation of these quality measures. Sup-
pose an automated tool has an extraction strategy of vari-
ant-protein-gene: variants that the automated tool as well
as manual curation assign to a same protein/gene are clas-
siﬁed as true positive (TP); variants that the tool assigns to
a protein/gene but are manually classiﬁed as discordant are
classiﬁed as false positive (FP); and variants that are
manually classiﬁed as TP, but assigned to the wrong
protein/gene by the tool are classiﬁed as (FN). Precision
is calculated as P = TP/(TP + FP); recall R = TP/
(TP + FN); and F-score = 2  P  R/(P + R). F-score is
a number between 0 and 1, and a value of 1 is attained only
when an automated tool produces neither FP nor FN. P, R
and F can also be applied for extraction of variants alone.against the variants curated by automated tools
A (human cervical cancer cells); V600E (BRAF thyroid cancer cells);
-cell line); H294R (adrenocortical line); A375M, F30K, F5K, T14D, T24C,
n), C184L, A10L(viral), A11L(viral), A52R(viral), etc.
eumoniae R36A, A. Naeslundii T14V,Mycoplasma spp. G145T, Aeromonas
necoccus spp. D120S, Symbiodinium spp. H10K, Yeast strain S288C, clone
smids P15A), transgenic mouse model G93A), etc.
), A9145C (antifungal), etc.
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Some inherent limitations of automated tools that reduce
eﬀectiveness are as follows. (i) They are not devised to col-
lect information on experimental procedures and eﬀects of
the variants [26]. (ii) They may not eﬀectively extract vari-
ants listed in the ﬁgures in the papers. (iii) They have pri-
marily been optimized to extract point mutations only.
(iv) They may not grab the artiﬁcial variants cited in papers
properly. For example, (a) a variant can be mentioned as
CTGTA(G)TGTGT to CTGTA(A)TGTGT where G is
changed to A and such a variant may be missed by the tool;
(b) similarly, a paper may mention ‘functional importance
of alanine at position 234 by changing it into His, Arg, Cys
and Trp’. Such artiﬁcial variants are worthy of curation
due to their functional implication(s) but are prone to be
missed by the automated curation tools). (v) Precision
and recall rate may vary depending upon the type of liter-
ature sets and proteins.
Interpretation of variants
Interpretation of a genetic variant primarily depends upon
its type and all available information on its pathogenicity
determinants. Variant-related information is predomi-
nantly extracted manually [5]. A list of various types of
information that needs extract during interpretation of a
variant is presented in Figure S1. All information about
pathogenicity determinants of a variant should be inte-
grated in order to come to a correct yet safe conclusion
on pathogenicity of the variant.
LSDBs (such as Leiden’s open variation database
(LOVD), human gene mutation database (HGMD)),
dbSNP as well as genetic testing centers interpret variants
in a spectrum of interpretation such as: ‘pathogenic’; ‘prob-
ably pathogenic’; ‘possibly pathogenic’; ‘variant of
unknown signiﬁcance’ (VUS); ‘possibly nonpathogenic’;
‘probably nonpathogenic’; and ‘nonpathogenic’ [27].
Though the phrases used can diﬀer across the ﬁelds con-
cerned, their essence remains the same: HGMD uses ‘dis-
ease-causing’ for ‘pathogenic’. While some variants are
easy to interpret, interpretation of others might not be
straightforward [7,28]. There are also published guidelines
for the interpretation and reporting of the variants by
ACMG (American College of Medical Genetics) [29]. Non-
sense mutations, frameshift mutations, splice-site muta-
tions, large insertion, deletion, indel, duplication
mutations, and point mutations at initiation and stop
codons are easy to interpret because their eﬀects are delete-
rious. Missense mutations are the hardest ones to interpret;
it is desirable to interpret them as VUS if supporting infor-
mation is lacking [29,30]. Similarly, if supporting informa-
tion is lacking for intronic and small in-frame insertion and
deletion variants in the coding region, the safest interpreta-
tion of them that we can suggest is VUS. Similarly, it is
safer to interpret novel synonymous variants with no sup-
porting data as VUS because they can be suspected offorming cryptic splice-sites [21]. The same applies for deep
intronic variants—this is supported by the fact that there
are many disease causing variants reported deep in the
introns of genes like HBB and CFTR (http://www.glo-
bin.bx.psu.edu/hbvar/menu.html and www.genet.sickk-
ids.on.ca/, respectively).
Updates of information about a variant over a time may
bring about conﬂict during interpretation of the variant.
However, we can safeguard the interpretation so that
updates of information do not alter the interpretation so
drastically (pathogenic spectrum to nonpathogenic spec-
trum and vice versa) as to mislead the clinical decisions.
Novel missense mutations pose diﬃculty in making clinical
decisions. In silico predictions and conservativeness of such
variants may help to determine the pathogenicity. If possi-
ble, segregation analysis in the family and observation in
the ethnicity-matched healthy population should be done
to determine the pathogenicity.
The interpretation of a genetic variant by genetic testing,
database and research body may not be the same. To stan-
dardize interpretation of variants, our suggestions are: (i)
there should be universal standard guidelines about the
process of determining the pathogenicity of the variants;
(ii) a variant should be interpreted in such as way that
update in future will not change the interpretation drasti-
cally (like a variant previously interpreted as ‘pathogenic’
should not be ‘nonpathogenic’ in future) and (iii) a variant
which has not been classiﬁed as ‘not disease causing’ or
‘disease causing’ (e.g., a wide spectrum of interpretation
between these two) should be re-interpreted from time to
time owing to update of information.
Conclusion
The curation of genetic variants from literature is an essen-
tial part of genetic testing as well as various other
researches including building of mutational databases. Ide-
ally, it is imperative that curation should produce 100%
sensitivity and speciﬁcity. Studying the genotype-pheno-
type correlation or the diagnostic signiﬁcance of variants
is challenging and requires speciﬁc as well as reproducible
results. It is crucial that papers describing the genetic vari-
ants get clear exposure to the information seekers. To
avoid or at least reduce diﬃculties in curation, authors
should write papers with variants focusing primarily on
standard nomenclature and become more speciﬁc by men-
tioning variants at cDNA level. In recent years, the num-
bers of papers following the standard nomenclature of
variants is increasing which is making curation more eﬀec-
tive and easier. Moreover, the authors should avoid men-
tioning the variants only at amino acid level. Apart from
this, to help for eﬀective retrieval and curation, journals
and publishers should urge authors to follow the standard
nomenclature such as HGNC and HGVS for the gene and
variant names, respectively, as conditions for the publica-
tion of papers [11]. These practices will increase accuracy,
speed, sensitivity, and speciﬁcity in manual as well as in
324 Genomics Proteomics Bioinformatics 10 (2012) 317–325automated curation. For large scale curation, prospective
research in bioinformatics should focus on integration of
automated and manual curation methods that will obviate
the limitations of either approach. To bring uniformity in
interpretation of variants, standard guidelines for the inter-
pretation of variants should be developed.Competing interests
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